Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-01-11

Clinical Trial Update: A Study of the Safety and Efficacy of MK-3577 in Participants With Type 2 Diabetes Mellitus (MK-3577-009) [Phase 2]

View source ↗

Summary

Phase 2 study of MK-3577 in type 2 diabetes mellitus was terminated with posted results in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • MK-3577

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Type 2 Diabetes Mellitus | Phase 2 | Status: TERMINATED | Results posted: 2017-01-11